上海交通大学学报（医学版）

›› 2010, Vol. 30 ›› Issue (3): 275-.

• 专题报道（甲状腺癌核素治疗） • 上一篇    下一篇

失分化型甲状腺癌再分化研究进展

侯莎莎, 综述；王 辉, 审校   

  1. 上海交通大学 医学院新华医院核医学科, 上海 200092
  • 出版日期:2010-03-25 发布日期:2010-03-24
  • 作者简介:侯莎莎（1983—）, 女, 硕士生；电子信箱: housha515@sina.com。

Research progress of redifferentiation of dedifferentiated thyroid carcinoma

HOU Sha-sha, reviewer；WANG Hui, reviser   

  1. Department of Nuclear Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China
  • Online:2010-03-25 Published:2010-03-24

PDF (PC)

1523

摘要：

甲状腺碘代谢相关基因是甲状腺癌分化的重要标志。分化型甲状腺癌由于失去或下调一系列碘代谢相关基因的表达而发生失分化，导致癌细胞丧失对放射性碘（131I）的摄取能力。因此，再分化的研究对甲状腺癌131I治疗具有重要意义。研究证实，BRAF基因突变与甲状腺乳头状癌的失分化现象密切相关。文章就通过上调甲状腺碘代谢相关基因表达和抑制BRAF基因突变而使失分化型甲状腺癌再分化的研究进展作一综述。

关键词: 失分化型甲状腺癌, 放射性碘, 甲状腺碘代谢相关基因, BRAF基因突变

Abstract:

Thyroid iodide-metabolizing genes are established markers for differentiation of thyroid carcinoma. The loss or downregulation of iodide-metabolizing genes represents progression of dedifferentiation of differentiated thyroid carcinoma, which results in the disability to take up and accumulate radioiodine (131I). Therefore, the research of redifferentiation is important for 131I therapy of thyroid carcinoma. BRAF gene mutation has been confirmed to be closely related to the dedifferentiation of papillary thyroid carcinoma. The research progress of redifferentiation of dedifferentiated thyroid carcinoma by up-regulation of thyroid iodide-metabolizing genes expression and suppression of BRAF mutation is reviewed in this paper.

Key words: dedifferentiated thyroid carcinoma, radioiodine, thyroid iodide-metabolizing gene, BRAF gene mutation